An observational study in Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals. Recruiting at 22 sites in Italy. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Hidradenitis Suppurativa by Novartis — 9 open to participants now, 14 under way, 3 of them phase 3. Hidradenitis Suppurativa · Novartis.
Among the 21 studies in Hidradenitis Suppurativa by Novartis, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is one of 7 that started in 2025, is one of 10 observational ones, reaches primary completion later than 11 of the 13 other live ones, and was the 14th registered.
286 studies on the registry are indexed under Hidradenitis Suppurativa; 89 are open to participants now.
Browse Hidradenitis Suppurativa studies →9 of the 21 studies in Hidradenitis Suppurativa by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 9 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in China
Ages 18+
Novartis Pharmaceuticals · Sites in Korea, Republic of
Ages 6–100
Novartis Pharmaceuticals · Sites in Canada
Ages 18–100
By country, each count listing its studies:
Of the 63 Hidradenitis Suppurativa studies recruiting now, 35 (56%) set no upper age limit and 17 (27%) stop at 75 or younger; 13 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 175 across 73 observational studies indexed under Hidradenitis Suppurativa.
Median enrollment 545 across the 10 interventional studies, 125 across the 10 observational. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
9 of the studies in Hidradenitis Suppurativa by Novartis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06799000Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | 2027-05-17 |
| NCT06840392Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | 2027-06-03 |
| NCT06517732Novartis PharmaceuticalsStudy to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation | 2026-12-31 |
| NCT07690319Novartis PharmaceuticalsA Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients | 2027-03-15 |
| NCT05921994Novartis PharmaceuticalsLong Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa. | 2027-03-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 21 studies in Hidradenitis Suppurativa by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to generate real-world evidence to fill knowledge gaps regarding the response to secukinumab in patients with moderate to severe HS, its treatment patterns, the clinical characteristics of patients on secukinumab, healthcare resource utilization and the economic impact of HS in Italy.
The study population will include male and female adult patients (aged ≥ 18 years) with a diagnosis of moderate or severe HS and initiating treatment with secukinumab according to clinical practice
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Study participants eligible for inclusion in this study must meet all the following criteria:
1. Male and Female patients who provide written and privacy form (ICF\&PF) to participate in the study.
2. Aged ≥ 18 years at ICF\&PF signature. 3. Patients with moderate or severe HS (IHS4 and/or Hurley staging system, as assessed by the investigators) at index date.
4. The start of secukinumab is within 30 days after the ICF\&PF signature (enrolment), as per local standard clinical practice. Patients were not treated with secukinumab before enrolment within the Managed Access Program (MAP). The initiation of secukinumab is based on dermatologist's own practice, regardless of study participation.
For HRU and economic burden only:
5. Patients who provide written ICF\&PF to allow the use of secondary (administrative) data for the purposes of this study.
6. Patients with more than 12 months of residence inside the area of competence of the LHU (applicable only to study sites associated with the 6 LHUs).
Exclusion Criteria:
Study participants meeting any of the following criteria are not eligible for inclusion in this study:
7. Participation in an ongoing clinical trial. 8. Any medical or psychological condition that may prevent study participation, based on practitioners' decision-making.
For HRU and economic burden only:
9. Patients will be excluded if the unique identifier does not allow them to be identified in the LHU administrative databases related to the site where they were enrolled.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Proportion of patients achieving 55% reduction in IHS4 (IHS4-55) during the observational period.
Proportion of patients achieving International Hidradenitis Suppurativa Severity Score System 55% reduction(IHS4-55) during the observational period. The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. Determining IHS4 requires counting nodules, abscesses and draining tunnels/sinus tracts, which is easy to calculate. The IHS4 score is calculated as the number of nodules (multiplied by 1) plus the number of abscesses (multiplied by 2) plus the number of draining tunnels (multiplied by 4). A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS
Time frame: Baseline,6 months and 1 and 1,5 years after initiation of secukinumab
Proportion of patients achieving 55% reduction in IHS4 (IHS4-55) stratified by dosing
The proportion of patients achieving 55% reduction in IHS4 (IHS4-55) stratified by dosing (q4w / q2w regimen), at 6 months, 1 and 1.5 years after initiation of secukinumab treatment. The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. Determining IHS4 requires counting nodules, abscesses and draining tunnels/sinus tracts, which is easy to calculate. The IHS4 score is calculated as the number of nodules (multiplied by 1) plus the number of abscesses (multiplied by 2) plus the number of draining tunnels (multiplied by 4). A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS
Time frame: 6 months, 1 and 1.5 years after initiation of secukinumab treatment
Proportion of patients achieving 75% reduction in IHS4 (IHS4-75) and 100% reduction in IHS4 (IHS4-100)
The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. Determining IHS4 requires counting nodules, abscesses and draining tunnels/sinus tracts, which is easy to calculate. The IHS4 score is calculated as the number of nodules (multiplied by 1) plus the number of abscesses (multiplied by 2) plus the number of draining tunnels (multiplied by 4). A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS
Time frame: 6 months, 1 and 1.5 years after initiation of secukinumab treatment
Proportion of patients achieving 50% reduction in HiSCR (HiSCR-50) and 75% reduction in HiSCR (HiSCR-75)
The Hidradenitis Suppurativa Clinical Response (HiSCR) is defined as a ≥ 50% reduction in total AN count (abscesses + inflammatory nodules), and no increase in abscesses or draining tunnels when compared with baseline.
Time frame: 6 months, 1 and 1.5 years after initiation of secukinumab treatment
Number, type, and localization of HS lesions
lesion spread is defined as total abscess and inflammatory nodule count (AN) or draining fistulae in a body region not seen at baseline
Time frame: baseline, 6 months, 1 and 1.5 years after initiation of secukinumab treatment
Change of total abscess and inflammatory nodule count
Time frame: 6 months, 1 and 1.5 years after initiation of secukinumab treatment
Proportion of patients receiving up-titration
Proportion of patients receiving up-titration (q4w-to-q2w) of secukinumab
Time frame: Within 6 months, 1 and 1.5 years after initiation of secukinumab treatment
Proportion of patients receiving down-titration
Proportion of patients receiving down-titration (q2w-to-q4w) of secukinumab
Time frame: within 6 months, 1 and 1.5 years after initiation of secukinumab treatment
Time to up-titration and down-titration
Time to up-titration (q4w-to-q2w) and down-titration (q2w-to-q4w) of secukinumab
Time frame: Up to 1.5 years
Proportion of patients switching from q4w to q2w treatment
Proportion of patients switching from q4w to q2w treatment with secukinumab after dose reduction.
Time frame: 6 months and 1.5 years after initiation of secukinumab treatment
Proportion of patients who receive more than one up- and/or down-titration
Proportion of patients who receive more than one up- and/or down-titration of secukinumab
Time frame: within 6 months, 1 and 1.5 years after initiation of secukinumab treatment
Demographics of adult patients with moderate or severe HS
Descriptive statistics will be performed
Time frame: Baseline
Proportion of patients achieving a 5-point reduction of Dermatology life quality index (DLQI) score.
The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score ranges from 0 to 30, with higher scores indicating greater HRQoL impairment
Time frame: 6 months, 1 and 1.5 years after initiation of secukinumab treatment
Change in DLQI score from baseline
The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score ranges from 0 to 30, with higher scores indicating greater HRQoL impairment
Time frame: Baseline, 6 months, 1 and 1.5 years after initiation of secukinumab
Clinical characteristics of adult patients with moderate to severe HS
Clinical characteristics of adult patients with HS moderate or severe
Time frame: Up to 1.5 years
Proportion of patients with new draining tunnel
Proportion of patients with new draining tunnel(s) (fistulae/sinuses)
Time frame: 6 months, 1 and 1.5 years after initiation of secukinumab treatment
Number of areas affected and proportion of patients with additional area involvement
Time frame: 6 months, 1 and 1.5 years after initiation of secukinumab treatment
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab
Proportion of patient as per clinical practice
Time frame: Up to 1.5 years
Time of initiation of concomitant medications
Time of initiation of concomitant medications (after the initiation of secukinumab)
Time frame: Baseline, 6 months, 1 and 1.5 years after initiation of secukinumab treatment
Duration of treatment with concomitant medications
Duration of treatment with concomitant medications in a flexible dosing regimen of secukinumab
Time frame: Up to 1.5 years
Proportion of patients undergoing tapering of concomitant medications
Proportion of patients undergoing tapering of concomitant medications in a flexible dosing regimen of secukinumab.
Time frame: Baseline, 6 months, 1 and 1.5 years after initiation of secukinumab treatment
Number and type of surgical interventions
number and type of surgical interventions (minor and major surgical excision; inpatient, outpatient, or self-treatment at home) in a flexible dosing regimen of secukinumab (q4w and q2w)
Time frame: 6 months, 1 and 1.5 years after initiation of secukinumab
Reason for surgical intervention
Time frame: Up to 1.5 years after initiation of secukinumab
Duration of discontinuation/pause of secukinumab treatment before surgery
Time frame: Up to 1.5 years after initiation of secukinumab
Duration of discontinuation/pause of secukinumab treatment after surgery
Time frame: Up to 1.5 years after initiation of secukinumab
Reduction in the number of surgical procedures
Time frame: Up to 1.5 years after initiation of secukinumab
Identification of potential predictors using multivariable analysis
Time frame: Up to 1.5 years after initiation of secukinumab treatment
Descriptive statistics of pain
Descriptive statistics of pain (Numerical Skin Pain Rating Scale).
Time frame: 6 months, 1 and 1.5 years after initiation of secukinumab treatment
Proportion of patients achieving a 30% reduction of Pain Numerical Rating scale (NRS30)
The Numerical Skin Pain Rating Scale (NRS) is a scale in which the respondent selects a whole number (0-10 integers) that best reflects the intensity of his/her worst skin pain ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine).To assess this, the patient should concentrate on the worst pain that his/her skin lesions has generated during the previous 24 hours. NRS30 is a specific threshold used in the assessment of pain reduction in patients with HS. It is defined as a ≥30% and ≥2-point reduction in skin pain on the NRS.
Time frame: 6 months, 1 and 1.5 years after initiation of secukinumab treatment
Number of patients with secukinumab AEs in routine clinical practice
Number of patients with secukinumab adverse events (AEs) in routine clinical practice
Time frame: Up to 1.5 years after initiation of secukinumab treatment
Hospital Anxiety and Depression Scale [HADS] score
The HADS is a widely used screening tool that helps to identify possible or probable instances of anxiety and depression among patients in non-psychiatric hospital settings. It consists of 14 items, with 7 items related to anxiety (HADS-A) and 7 related to depression (HADS-D), collecting how the patient was feeling in the previous week. Each item is scored from 0 to 3, leading to a maximum score of 21 for each subscale. The HADS is beneficial because it excludes somatic symptoms, which might be caused by physical health problems rather than psychological conditions. It is a quick, reliable, and valid measure that can be self-administered, making it a practical tool for clinicians.
Time frame: 6 months, 1 and 1.5 years after secukinumab initiation
Healthcare Resource Utilization of adult patients with HS
describe Healthcare Resource Utilization of adult patients with HS 12 months before and 12 months after secukinumab treatment initiation with administrative claims data
Time frame: 2 months before and 12 months after secukinumab treatment initiation
Costs of HS covered by the Italian National Health System
Costs of HS covered by the Italian National Health System (Servizio Sanitario Nazionale, SSN) with administrative Claims data
Time frame: 12 months before and 12 months after secukinumab treatment initiation
Direct costs not covered by the SSN and indirect costs of HS
Direct costs not covered by the SSN and indirect costs of HS evaluated through a structured interview between physicians and patients.
Time frame: 12 months before and 12 months after secukinumab treatment initiation
Analysis on HS-related surgeries per patient and related direct costs covered by SSN
HS-related surgeries and estimate direct costs of HS-related surgeries covered by the SSN during the period from the date of first HS diagnosis to 12 months after secukinumab treatment initiation with administrative Claims data
Time frame: 12 months after secukinumab treatment initiation
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Sep 2028, 33 months after the start.
Of 46 observational studies under Hidradenitis Suppurativa, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 25. This study's planned 33 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.